Patients with targetable alterations experience higher response rates to targeted therapy vs immunotherapy.1
Optimizing treatment requires all the answers
Get the complete
picture before
choosing treatment.
NCCN-guideline recommended testing for solid tumors.1-13
All solid tumors
Bladder
Breast
Cholangiocarcinoma
Colorectal
Endometrial
Gastric and Gastroesophageal
GIST
Lung
Melanoma
Ovarian
Pancreatic
Prostate
Thyroid
ALK
ATM
BRAF
BRAF V600E
BRAF V600K
BRCA1
BRCA2
CDK12
EGFR
ERBB2 (HER2)
ESR1
FGFR2
FGFR3
IDH1
KIT
KRAS
MET
MSI
NRAS
NTRK
PDGFRA
PIK3CA
RET
ROS1
There are FDA-approved therapies available for all solid tumors with NTRK fusions and MSI status.
Current as of September 2020.
Targeted treatment improves outcomes.
Liquid biopsy offers critical advantages over tissue testing.
Leading with liquid-first testing can help inform clinical decisions faster than tissue.